Table 1.
Risk factors, clinical, angiographic and intervention data in Women with non-premature (≥60 years), premature (45–60 years) and very premature (<45 years) CAD.
| Variable | Total women (n = 936) | Non-premature (n = 576, 61.5%) | Premature (n = 299, 31.9%) | Very premature (n = 61, 6.5%) | X2 test for trend (P value) |
|---|---|---|---|---|---|
| Risk factors | |||||
| Hypertension | 600(64.0) | 397(68.9) | 179(59.9) | 23(37.7) | <0.001 |
| Diabetes | 378(40.3) | 235(40.8) | 127(42.5) | 16(26.2) | 0.233 |
| Total cholesterol (mean ± SD) | 156 ± 45.5 | 152.5 ± 44.4 | 164.4 + 46.4 | 166.7 ± 38.3 | 0.009 |
| Cholesterol ≥200 mg/dl | 133(14.2) | 70(12.2) | 52(17.4) | 11(18.0) | 0.031 |
| Cholesterol ≥170 mg/dl | 263(28.1) | 144(25.0) | 101(33.8) | 18(29.5) | 0.027 |
| Non-HDL cholesterol (mean ± SD) | 93.0 ± 60.3 | 87/4 ± 58.4 | 105.8 ± 62.0 | 106.9 ± 58.7 | 0.001 |
| Non-HDL cholesterol ≥130 mg/dl | 237(25.3) | 122(21.2) | 99(33.1) | 16(26.2) | 0.003 |
| Non-HDL cholesterol ≥100 mg/dl | 442(47.2) | 243(42.2) | 161(53.8) | 38(62.3) | <0.001 |
| LDL cholesterol (mean ± SD) | 104.3 ± 43.7 | 104.8 ± 44.8 | 103.3 ± 42.2 | 104.0 ± 41.1 | 0.901 |
| LDL cholesterol ≥100 mg/dl | 404(43.2) | 251(43.6) | 123(41.1) | 30(49.2) | 0.959 |
| LDL cholesterol ≥70 mg/dl | 636(67.9) | 384(66.7) | 213(71.2) | 39(63.9) | 0.673 |
| Triglycerides (median, IQR mg/dl) | 135(101–189) | 138(101–190) | 133(100–190) | 139(103–181) | 0.763 |
| Triglycerides ≥150 mg/dl | 358(38.2) | 220(38.2) | 115(38.4) | 23(37.7) | 0.935 |
| Smoking/Tobacco (ever) | 73(7.8) | 38(6.6) | 27(9.0) | 8(13.1) | 0.044 |
| Chronic KD, creatinine ≥2 mg/dl | 12(1.3) | 10(1.7) | 2(0.7) | 0(0.0) | 0.108 |
| Uninsured status |
388(41.5) |
228(38.8) |
130(43.5) |
36(59.0) |
0.003 |
| Previous cardiovascular status | |||||
| Coronary intervention | 99(10.6) | 68(11.8) | 24(8.0) | 7(11.5) | 0.259 |
| Coronary bypass surgery | 24(2.6) | 19(3.3) | 4(1.3) | 1(1.6) | 0.107 |
| Congestive heart failure | 6(0.6) | 5(0.9) | 1(0.3) | 0(0.0) | 0.258 |
| Aspirin | 317(33.9) | 203(35.2) | 95(31.8) | 19(31.1) | 0.282 |
| Beta-blockers | 347(37.1) | 215(37.3) | 108(36.1) | 24(39.3) | 0.993 |
| Statins |
432(46.2) |
284(49.3) |
125(41.8) |
23(37.7) |
0.013 |
| Clinical presentation | |||||
| Acute coronary syndromes | 927(98.9) | 544(94.4) | 281(94.0) | 60(98.4) | 0.052 |
| STEMI | 339(36.2) | 201(36.9) | 113(40.2) | 25(41.7) | 0.245 |
| NSTEMI/Unstable angina | 546(58.3) | 343(60.1) | 168(59.8) | 35(58.3) | 0.414 |
| Chronic coronary syndrome |
9(1.0) |
32(5.6) |
18(6.0) |
1(1.6) |
0.411 |
| Left ventricular function | |||||
| Mean ejection fraction (EF) | 46.2 ± 10.2 | 45.7 + 10.0 | 47.4 + 10.5 | 44.2 ± 9.1 | 0.099 |
| EF <30% | 33(3.6) | 19(3.3) | 12(4.1) | 2(3.3) | 0.866 |
| EF 30–45% | 463(50.1) | 303(53.2) | 129(44.0) | 31(50.8) | 0.293 |
| EF >45% |
428(46.3) |
248(43.5) |
152(51.9) |
28(45.9 |
0.414 |
| CAD anatomy | |||||
| LMCA | 42(4.5) | 25(4.3) | 13(4.3) | 3(4.9) | 0.885 |
| RCA | 448(47.9) | 285(49.5) | 135(45.2) | 28(45.9) | 0.264 |
| LAD | 761(81.3) | 469(81.4) | 243(81.3) | 49(80.3) | 0.861 |
| LCX | 451(48.2) | 282(49.0) | 138(46.2) | 31(50.8) | 0.761 |
| Single-vessel disease | 8(0.9) | 237(41.1) | 131(43.8) | 25(41.0) | 0.885 |
| Double vessel disease | 393(42.0) | 203(35.2) | 110(36.8) | 25(41.0) | 0.818 |
| Triple vessel disease | 338(36.1) | 131(22.7) | 55(18.4) | 11(18.0) | 0.425 |
|
Number of stents deployed | |||||
| 1 stent | 563(60.1) | 337(58.5) | 184(61.5) | 42(68.9) | 0.712 |
| 2 stents | 277(29.6) | 179(31.1) | 84(28.1) | 14(23.0) | 0.536 |
| ≥3 stents |
80(8.6) |
51(8.8) |
24(8.1 |
5(8.2 |
0.926 |
| Deaths in-hospital (%) | 9(1.0) | 7(1.2) | 2(0.7) | 0(0.0) | 0.265 |
Numbers ± indicate 1 SD. Numbers in parenthesis are percent. CAD coronary artery disease; CKD chronic kidney disease; HDL high density lipoprotein; LAD left anterior descending; LCX left circumflex; LDL low density lipoprotein; LMCA left main coronary artery; NSTEMI non ST segment elevation myocardial infarction; RCA right coronary artery; STEMI ST segment elevation myocardial infarction.